stockrow
Friday 6 November 2026
Export ACRV’s income statement to Excel — free account
Acrivon Therapeutics, Inc.
ACRV Healthcare Biotechnology
- EPS
- +21.8%
- Free cash flow
- +12.6%
Quarter to June 2026, against a year earlier
1.59
0.02
+1.27%
Follow ACRV
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 11 | 11 | 11 | 0.0% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | (5) | (16) | (31) | (60) | (81) | (78) | (74) | +71.1% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | (5) | (16) | (31) | (60) | (81) | (78) | (74) | +71.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (3.70) | (9.32) | (7.56) | (2.74) | (2.38) | (2.02) | (1.88) | (11.4%) | ||||||
| Cash flow | — | — | — | — | (1.96) | (8.02) | (7.31) | (1.93) | (1.94) | (1.65) | (1.50) | (3.3%) | ||||||
| Capex | — | — | — | — | (0.01) | (0.14) | (0.53) | (0.06) | (0.08) | (0.04) | (0.03) | +32.8% | ||||||
| Free cash flow | — | — | — | — | (1.97) | (8.16) | (7.83) | (1.99) | (2.03) | (1.70) | (1.53) | (2.9%) | ||||||
| Book value | — | — | — | — | 0.88 | 56.62 | 41.36 | 5.49 | 5.23 | 2.92 | 2.07 | +27.3% | ||||||
| Shares, m | — | — | — | — | 1 | 2 | 4 | 22 | 34 | 39 | 39 | +93.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (3) | (14) | (30) | (43) | (66) | (64) | (63) | +86.7% | |||||
| Capex | — | — | — | — | 0 | 0 | (2) | (1) | (3) | (2) | (1) | +156.6% | ||||||
| Free cash flow | — | — | — | — | (3) | (14) | (32) | (44) | (68) | (65) | (64) | +87.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | 97 | 126 | 116 | 164 | 105 | 80 | +148.5% | |||||
| Net debt | — | — | — | — | (2) | (100) | (128) | (127) | (179) | (119) | (90) | +137.1% | ||||||
| Shareholders’ equity | — | — | — | — | 1 | 99 | 170 | 121 | 177 | 113 | 87 | +145.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (29.87) | (21.66) | (37.80) | (48.11) | (47.75) | (57.61) | (47.7) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (47.77) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 0.00 | 100.82 | (42.50) | (41.41) | (54.07) | (53.86) | (64.63) | (53.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 42 | 44 | 61 | 78 | 76 | — | +16.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Acrivon Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings, Inc. | $72.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −55.29% (below 0%: shrinking) | 100.00% | (516.86%) | Compare |
| MNOV MediciNova, Inc. | $71.4M | — (loss-making) | — (loss-making) | +240.56% (above 0%: growing) | n/m | +16.75% (above 0%: growing) | 69.33% | (554.36%) | Compare |
| NTRB Nutriband Inc. | $67.8M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| ACRV Acrivon Therapeutics, Inc. | $67.3M | — (loss-making) | — | — | n/m | +12.59% (above 0%: growing) | 0.00% | 0.00% | |
| CSBR Champions Oncology, Inc. | $66.3M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| COYA Coya Therapeutics, Inc. | $65.9M | — (loss-making) | — (loss-making) | +48.96% (above 0%: growing) | n/m | −27.79% (below 0%: shrinking) | 100.00% | (2,891.67%) | Compare |
| CNXU Conexeu Sciences Inc. | $65.4M | — (loss-making) | — | — | n/m | −1,084.33% (below 0%: shrinking) | — | 0.00% | Compare |
| MAIA MAIA Biotechnology, Inc. | $64.2M | — (loss-making) | — | — | n/m | −63.23% (below 0%: shrinking) | — | 0.00% | Compare |
| NORD Nordicus Partners Corporation | $63.2M | — (loss-making) | — | −99.58% (below 0%: shrinking) | n/m | +62.18% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $66.1M | — | — | +4.42% | — | −41.54% | 84.67% | (103.13%) |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
10.50%
Entities affiliated with RA Capital Management
28.70%
Chione Limited
9.00%
Peter Blume-Jensen, M.D., Ph.D.
7.60%
Kristina Masson, Ph.D., M.B.A.
7.60%
Sands Capital Life Sciences Pulse Fund II, L.P.
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement